Robert C Green

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1663546/publications.pdf

Version: 2024-02-01

236 papers	16,124 citations	34016 52 h-index	20307 116 g-index
269 all docs	269 docs citations	269 times ranked	22795 citing authors

#	Article	IF	Citations
1	ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 2013, 15, 565-574.	1.1	2,186
2	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
3	Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>. JAMA - Journal of the American Medical Association, 2009, 302, 2557.	3.8	542
4	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	15.2	508
5	Disclosure ofAPOEGenotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254.	13.9	490
6	Diagnostic Clinical Genome and Exome Sequencing. New England Journal of Medicine, 2014, 370, 2418-2425.	13.9	488
7	Depression as a Risk Factor for Alzheimer Disease. Archives of Neurology, 2003, 60, 753.	4.9	485
8	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
9	Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. American Journal of Human Genetics, 2016, 98, 1067-1076.	2.6	432
10	Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genetics in Medicine, 2012, 14, 361-384.	1.1	418
11	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	2.6	342
12	Risk of Dementia Among White and African American Relatives of Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2002, 287, 329.	3.8	330
13	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
14	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
15	Relationship between Serum and Brain Carotenoids,<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î±</mml:mi></mml:mrow></mml:math>-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. Journal of Aging Research, 2013, 2013, 1-13.	0.4	213
16	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
17	Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL Study. Alzheimer Disease and Associated Disorders, 2008, 22, 94-97.	0.6	203
18	Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates. Circulation, 2016, 133, 1181-1188.	1.6	198

#	Article	IF	Citations
19	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
20	Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. American Journal of Human Genetics, 2019, 104, 76-93.	2.6	176
21	Newborn Sequencing in Genomic Medicine and Public Health. Pediatrics, 2017, 139, .	1.0	174
22	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
23	Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genetics in Medicine, 2012, 14, 405-410.	1.1	149
24	The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients. Annals of Internal Medicine, 2017, 167, 159.	2.0	145
25	GINA, Genetic Discrimination, and Genomic Medicine. New England Journal of Medicine, 2015, 372, 397-399.	13.9	141
26	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
27	The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials, 2014, 15, 85.	0.7	122
28	The BabySeq project: implementing genomic sequencing in newborns. BMC Pediatrics, 2018, 18, 225.	0.7	115
29	Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine, 2019, 21, 1100-1110.	1.1	111
30	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nature Medicine, 2021, 27, 1012-1024.	15.2	109
31	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	1.1	108
32	Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic. Journal of Clinical Oncology, 2020, 38, 2201-2205.	0.8	104
33	Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 2013, 15, 860-867.	1.1	99
34	Brain pathologies in extreme old age. Neurobiology of Aging, 2016, 37, 1-11.	1.5	94
35	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
36	Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest. JAMA Internal Medicine, 2017, 177, 344.	2.6	93

#	Article	IF	Citations
37	A taxonomy of medical uncertainties in clinical genome sequencing. Genetics in Medicine, 2017, 19, 918-925.	1.1	91
38	A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Medical Genetics, 2014, 15, 134.	2.1	84
39	The New Age of Patient Autonomy. JAMA - Journal of the American Medical Association, 2018, 320, 1973.	3.8	82
40	Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion, 2016, 56, 743-754.	0.8	81
41	A curated gene list for reporting results of newborn genomic sequencing. Genetics in Medicine, 2017, 19, 809-818.	1.1	79
42	Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Medicine, 2021, 13, 14.	3.6	79
43	Development of a clinical polygenic risk score assay and reporting workflow. Nature Medicine, 2022, 28, 1006-1013.	15.2	74
44	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 645-653.	0.4	72
45	Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genetics in Medicine, 2016, 18, 65-72.	1.1	71
46	Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematology,the, 2018, 5, e241-e251.	2.2	70
47	Evaluating Novel Therapies During the Ebola Epidemic. JAMA - Journal of the American Medical Association, 2014, 312, 1299.	3.8	63
48	A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	62
49	Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Medicine, 2017, 14, e1002190.	3.9	62
50	Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project. Genetics in Medicine, 2019, 21, 622-630.	1.1	61
51	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	1.1	60
52	Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. Arthritis Care and Research, 2018, 70, 823-833.	1.5	60
53	Genomic sequencing in clinical practice: applications, challenges, and opportunities. Dialogues in Clinical Neuroscience, 2016, 18, 299-312.	1.8	59
54	Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Review of Molecular Diagnostics, 2016, 16, 521-532.	1.5	58

#	Article	IF	Citations
55	Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project. Genetics in Medicine, 2018, 20, 1069-1076.	1.1	58
56	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. Journal of Clinical Oncology, 2018, 36, 3331-3339.	0.8	58
57	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
58	Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Science Translational Medicine, 2016, 8, 364ra151.	5.8	55
59	Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. Genetics in Medicine, 2019, 21, 2781-2790.	1.1	55
60	How to know when physicians are ready for genomic medicine. Science Translational Medicine, 2015, 7, 287fs19.	5.8	54
61	Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the â€œBenefit to Familiesâ€. Journal of Law, Medicine and Ethics, 2015, 43, 552-558.	0.4	53
62	Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Childrenâ€™s Hospital Gene Partnership Informed Cohort Oversight Board. Genetics in Medicine, 2014, 16, 547-552.	1.1	49
63	Parental Decision-Making Preferences in Neonatal Intensive Care. Journal of Pediatrics, 2016, 179, 36-41.e3.	0.9	49
64	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
65	Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics, 2019, 143, S6-S13.	1.0	47
66	Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project. Genetics in Medicine, 2021, 23, 1372-1375.	1.1	47
67	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 2017, 19, 787-795.	1.1	46
68	Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nature Medicine, 2019, 25, 1198-1204.	15.2	46
69	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biology of Blood and Marrow Transplantation, 2015, 21, 1308-1314.	2.0	45
70	Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project. Pediatrics, 2019, 143, S37-S43.	1.0	45
71	When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. American Journal of Bioethics, 2019, 19, 11-18.	0.5	44
72	Hospital Length of Stay in the First 100ÂDays after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2014, 20, 1819-1827.	2.0	43

#	Article	IF	Citations
73	Participants and Study Declinersâ€™ Perspectives About the Risks of Participating in a Clinical Trial of Whole Genome Sequencing. Journal of Empirical Research on Human Research Ethics, 2016, 11, 21-30.	0.6	41
74	Predispositional genome sequencing in healthy adults: design, participant characteristics, and early outcomes of the PeopleSeq Consortium. Genome Medicine, 2019, 11, 10.	3.6	41
75	â€˜Someday it will be the normâ€™: physician perspectives on the utility of genome sequencing for patient care in the MedSeqProject. Personalized Medicine, 2015, 12, 23-32.	0.8	40
76	A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLoS Medicine, 2018, 15, e1002631.	3.9	40
77	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	4.5	39
78	Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees. Genetics in Medicine, 2016, 18, 924-932.	1.1	39
79	Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study. Genetics in Medicine, 2017, 19, 537-545.	1.1	39
80	Gender and Byline Placement of Co-first Authors in Clinical and Basic Science Journals With High Impact Factors. JAMA - Journal of the American Medical Association, 2018, 319, 610.	3.8	39
81	Federal Right-to-Try Legislation â€” Threatening the FDAâ€™s Public Health Mission. New England Journal of Medicine, 2018, 378, 695-697.	13.9	39
82	Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network. Journal of Personalized Medicine, 2020, 10, 30.	1.1	39
83	Parents are interested in newborn genomic testing during the early postpartum period. Genetics in Medicine, 2015, 17, 501-504.	1.1	38
84	Analyzing and Reanalyzing the Genome: Findings from the MedSeq Project. American Journal of Human Genetics, 2019, 105, 177-188.	2.6	38
85	Design, methods, and participant characteristics of the Impact of Personal Genomics (PGen) Study, a prospective cohort study of direct-to-consumer personal genomic testing customers. Genome Medicine, 2014, 6, 96.	3.6	37
86	A One-Page Summary Report of Genome Sequencing for the Healthy Adult. Public Health Genomics, 2015, 18, 123-129.	0.6	37
87	Characteristics Associated With Preferences for Parent-Centered Decision Making in Neonatal Intensive Care. JAMA Pediatrics, 2018, 172, 461.	3.3	37
88	Communication challenges for nongeneticist physicians relaying clinical genomic results. Personalized Medicine, 2017, 14, 423-431.	0.8	36
89	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genetics in Medicine, 2018, 20, 132-141.	1.1	36
90	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. American Journal of Bioethics, 2016, 16, 3-11.	0.5	35

#	Article	IF	Citations
91	Association Between Financial Incentives and Participant Deception About Study Eligibility. JAMA Network Open, 2019, 2, e187355.	2.8	35
92	Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project. JAMA Pediatrics, 2021, 175, 1132.	3.3	35
93	Summarizing polygenic risks for complex diseases in a clinical whole-genome report. Genetics in Medicine, 2015, 17, 536-544.	1.1	34
94	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	2.0	34
95	When bins blur: Patient perspectives on categories of results from clinical whole genome sequencing. AJOB Empirical Bioethics, 2017, 8, 82-88.	0.8	34
96	Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. Journal of Clinical Oncology, 2017, 35, 636-644.	0.8	34
97	Navigating the researchâ€“clinical interface in genomic medicine: analysis from the CSER Consortium. Genetics in Medicine, 2018, 20, 545-553.	1.1	34
98	Returning actionable genomic results in a research biobank: Analytic validity, clinical implementation, and resource utilization. American Journal of Human Genetics, 2021, 108, 2224-2237.	2.6	34
99	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplantation, 2020, 55, 906-917.	1.3	33
100	Gatekeepers for pragmatic clinical trials. Clinical Trials, 2015, 12, 442-448.	0.7	32
101	Automated typing of red blood cell and platelet antigens from whole exome sequences. Transfusion, 2019, 59, 3253-3263.	0.8	32
102	Return of individual research results from genomic research: A systematic review of stakeholder perspectives. PLoS ONE, 2021, 16, e0258646.	1.1	32
103	An eMERGE Clinical Center at Partners Personalized Medicine. Journal of Personalized Medicine, 2016, 6, 5.	1.1	31
104	Patientsâ€™ perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project. Personalized Medicine, 2016, 13, 13-20.	0.8	31
105	Implications of Zero Suicide for Suicide Prevention Research. JAMA - Journal of the American Medical Association, 2018, 320, 1633.	3.8	30
106	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genetics in Medicine, 2021, 23, 603-605.	1.1	29
107	A New Scale Measuring Psychologic Impact of Genetic Susceptibility Testing for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2009, 23, 50-56.	0.6	28
108	Explaining, not just predicting, drives interest in personal genomics. Genome Medicine, 2015, 7, 74.	3.6	28

#	Article	IF	Citations
109	Professionally Responsible Disclosure of Genomic Sequencing Results in Pediatric Practice. Pediatrics, 2015, 136, e974-e982.	1.0	28
110	Genomeâ€wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. Alzheimer's and Dementia, 2020, 16, 1134-1145.	0.4	28
111	An international policy on returning genomic research results. Genome Medicine, 2021, 13, 115.	3.6	28
112	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	27
113	Reclassification of genetic-based risk predictions as GWAS data accumulate. Genome Medicine, 2016, 8, 20.	3.6	26
114	Reconciling Opportunistic and Population Screening in Clinical Genomics. Mayo Clinic Proceedings, 2019, 94, 103-109.	1.4	26
115	Polygenic risk scores in the clinic: Translating risk into action. Human Genetics and Genomics Advances, 2021, 2, 100047.	1.0	26
116	The Development of a Preference-Setting Model for the Return of Individual Genomic Research Results. Journal of Empirical Research on Human Research Ethics, 2015, 10, 107-120.	0.6	25
117	Genomic medicine in the military. Npj Genomic Medicine, 2016, 1, 15008.	1.7	25
118	Diet and exercise changes following direct-to-consumer personal genomic testing. BMC Medical Genomics, 2017, 10, 24.	0.7	25
119	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in Medicine, 2018, 20, 1544-1553.	1.1	25
120	Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. JAMA Oncology, 2022, 8, 835.	3.4	25
121	An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. Npj Genomic Medicine, 2018, 3, 21.	1.7	24
122	The impact of personal genomics on risk perceptions and medical decision-making. Nature Biotechnology, 2016, 34, 912-918.	9.4	23
123	Clinical research: Should patients pay to play?. Science Translational Medicine, 2015, 7, 298ps16.	5.8	22
124	Ethical considerations in genomic testing for hematologic disorders. Blood, 2017, 130, 460-465.	0.6	22
125	Racial minority group interest in direct-to-consumer genetic testing: findings from the PGen study. Journal of Community Genetics, 2017, 8, 293-301.	0.5	22
126	Sharing Patient Data Without Exploiting Patients. JAMA - Journal of the American Medical Association, 2020, 323, 505.	3.8	22

#	Article	IF	Citations
127	Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol. JAMA Network Open, 2020, 3, e2027092.	2.8	22
128	IRB practices and policies regarding the secondary research use of biospecimens. BMC Medical Ethics, 2015, 16, 32.	1.0	21
129	Effectiveness of a Webâ€Based Personalized Rheumatoid Arthritis Risk Tool With or Without a Health Educator for Knowledge of Rheumatoid Arthritis Risk Factors. Arthritis Care and Research, 2018, 70, 1421-1430.	1.5	20
130	Informed Consent and the Role of the Treating Physician. New England Journal of Medicine, 2018, 378, 2433-2438.	13.9	20
131	Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial. Patient Education and Counseling, 2019, 102, 976-983.	1.0	20
132	Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines. JAMA - Journal of the American Medical Association, 2021, 325, 221.	3.8	20
133	Participant Satisfaction With a Preference-Setting Tool for the Return of Individual Research Results in Pediatric Genomic Research. Journal of Empirical Research on Human Research Ethics, 2015, 10, 414-426.	0.6	19
134	Justification and authority in institutional review board decision letters. Social Science and Medicine, 2017, 194, 25-33.	1.8	19
135	Preferences for the Return of Individual Results From Research on Pediatric Biobank Samples. Journal of Empirical Research on Human Research Ethics, 2017, 12, 97-106.	0.6	19
136	Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. Journal of Infectious Diseases, 2021, 224, 1995-2000.	1.9	19
137	Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing: Findings From the BabySeq Study. Frontiers in Genetics, 2022, 13, 867371.	1.1	19
138	Disclosing genetic risk of Alzheimerâ€™s disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Education and Counseling, 2017, 100, 927-935.	1.0	18
139	Regulatory flexibility for COVID-19 research. Journal of Law and the Biosciences, 2020, 7, lsaa057.	0.8	18
140	Primary prevention trials in Alzheimer disease. Neurology, 2006, 67, S2-5.	1.5	18
141	The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study. BMC Medical Genomics, 2015, 8, 63.	0.7	17
142	When Participants in Genomic Research Grow Up: Contact and Consent atÂthe Age of Majority. Journal of Pediatrics, 2016, 168, 226-231.e1.	0.9	17
143	Psychosocial Factors Influencing Parental Interest in Genomic Sequencing of Newborns. Pediatrics, 2016, 137, S30-S35.	1.0	17
144	Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study. BMC Medicine, 2021, 19, 199.	2.3	17

#	Article	IF	Citations
145	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empirical Bioethics, 2016, 7, 106-115.	0.8	16
146	How Primary Care Providers Talk to Patients about Genome Sequencing Results: Risk, Rationale, and Recommendation. Journal of General Internal Medicine, 2018, 33, 877-885.	1.3	16
147	Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12002.	1.8	16
148	Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genetics in Medicine, 2021, 23, 1366-1371.	1.1	16
149	5-fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study. Cancer, 1985, 56, 2395-2398.	2.0	15
150	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	0.8	15
151	Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Molecular Genetics & Genomic Medicine, 2018, 6, 898-909.	0.6	15
152	COVID-19 Moves Medicine into a Virtual Space. Annals of Surgery, 2020, 272, e159-e160.	2.1	15
153	How could disclosing incidental information from whole-genome sequencing affect patient behavior?. Personalized Medicine, 2013, 10, 377-386.	0.8	14
154	Commentary on Hey and Kimmelman. Clinical Trials, 2015, 12, 116-118.	0.7	14
155	Ethics knowledge of recent paediatric residency graduates: the role of residency ethics curricula. Journal of Medical Ethics, 2016, 42, 809-814.	1.0	14
156	Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. Alzheimer's and Dementia, 2018, 14, 514-519.	0.4	14
157	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2145-2151.	2.0	14
158	Genetic counseling following directâ€to consumer genetic testing: Consumer perspectives. Journal of Genetic Counseling, 2021, 30, 329-334.	0.9	14
159	DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 979-988.	1.1	14
160	Molecular cancer screening: in search of evidence. Nature Medicine, 2021, 27, 1139-1142.	15.2	14
161	Brain levels of lutein (L) and zeaxanthin (Z) are related to cognitive function in centenarians. FASEB Journal, 2011, 25, 975.21.	0.2	14
162	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1815-1822.	2.0	13

#	Article	IF	Citations
163	Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in Health, 2018, 21, 1054-1061.	0.1	13
164	Challenging the Current Recommendations for Carrier Testing in Children. Pediatrics, 2019, 143, S27-S32.	1.0	13
165	Preferences for Return of Genetic Results Among Participants in the Jackson Heart Study and Framingham Heart Study. Circulation Genomic and Precision Medicine, 2019, 12, e002632.	1.6	13
166	A whole genome approach for discovering the genetic basis of blood group antigens: independent confirmation for P1 and Xg^a. Transfusion, 2019, 59, 908-915.	0.8	13
167	An ethics framework for consolidating and prioritizing COVID-19 clinical trials. Clinical Trials, 2021, 18, 226-233.	0.7	13
168	Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions. Pediatrics, 2021, 147, .	1.0	13
169	Promoting Informed Decision Making for Comparative Effectiveness Randomized Trials. JAMA Pediatrics, 2015, 169, 803.	3.3	12
170	Are hybrid umbilical cord blood banks really the best of both worlds?. Journal of Medical Ethics, 2015, 41, 272-275.	1.0	12
171	Multiple GYPB gene deletions associated with the Uâˆ’ phenotype in those of African ancestry. Transfusion, 2020, 60, 1294-1307.	0.8	12
172	Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People Living with Dementia. Journal of the American Geriatrics Society, 2020, 68, S37-S42.	1.3	12
173	Ethics of Cancer Clinical Trials in Low-Resource Settings. Journal of Clinical Oncology, 2014, 32, 3192-3196.	0.8	11
174	Comparison of multi-sample variant calling methods for whole genome sequencing. , 2014, 2014, 59-62.		11
175	Chemotherapy Parity Laws. JAMA Internal Medicine, 2014, 174, 1721.	2.6	11
176	The case for implementing sustainable routine, population-level genomic reanalysis. Genetics in Medicine, 2020, 22, 815-816.	1.1	11
177	Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents. BMC Pediatrics, 2020, 20, 222.	0.7	11
178	The Genetic Privacy of Presidential Candidates. New England Journal of Medicine, 2008, 359, 2192-2193.	13.9	10
179	The impact of genetic counselorsâ€™ use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimerâ€™s disease. Patient Education and Counseling, 2018, 101, 817-823.	1.0	10
180	Protecting clinical trial participants and study integrity in the age of social media. Cancer, 2018, 124, 4610-4617.	2.0	10

#	Article	IF	Citations
181	Return of individual research results: What do participants prefer and expect?. PLoS ONE, 2021, 16, e0254153.	1.1	10
182	Reply to S. Gupta et al. Journal of Clinical Oncology, 2015, 33, 1414-1414.	0.8	9
183	Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer. Cancer, 1986, 58, 2389-2392.	2.0	8
184	Revolution or Reform in Human Subjects Research Oversight. Journal of Law, Medicine and Ethics, 2012, 40, 922-929.	0.4	8
185	A randomized trial Examining The Impact Of Communicating Genetic And Lifestyle Risks For Obesity. Obesity, 2016, 24, 2481-2490.	1.5	8
186	Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium. Personalized Medicine, 2019, 16, 325-333.	0.8	8
187	Allocating scarce life-saving resources: the proper role of age. Journal of Medical Ethics, 2021, 47, 836-838.	1.0	8
188	The price of whole-genome sequencing may be decreasing, but who will be sequenced?. Personalized Medicine, 2017, 14, 203-211.	0.8	7
189	Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs. JAMA - Journal of the American Medical Association, 2018, 319, 2167.	3.8	7
190	Communication Predictors of Patient and Companion Satisfaction with Alzheimerâ€™s Genetic Risk Disclosure. Journal of Health Communication, 2018, 23, 807-814.	1.2	7
191	Reconciling newborn screening and a novel splice variant in BTD associated with partial biotinidase deficiency: a BabySeq Project case report. Journal of Physical Education and Sports Management, 2018, 4, a002873.	0.5	7
192	Predictive and Precision Medicine with Genomic Data. Clinical Chemistry, 2020, 66, 33-41.	1.5	7
193	Educating military primary health-care providers in genomic medicine: lessons learned from the MilSeq Project. Genetics in Medicine, 2020, 22, 1710-1717.	1.1	7
194	The limits of acceptable political influence over the FDA. Nature Medicine, 2021, 27, 188-190.	15.2	7
195	Family health history reporting is sensitive to small changes in wording. Genetics in Medicine, 2016, 18, 1308-1311.	1.1	6
196	Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight. JAMA - Journal of the American Medical Association, 2019, 322, 1553.	3.8	6
197	Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value in Health, 2020, 23, 559-565.	0.1	6
198	From Sequence Data to Returnable Results: Ethical Issues in Variant Calling and Interpretation. Genetic Testing and Molecular Biomarkers, 2017, 21, 178-183.	0.3	5

#	Article	IF	Citations
199	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. PLoS ONE, 2018, 13, e0203179.	1.1	5
200	Development and Validation of a Comprehensive Genomics Knowledge Scale. Public Health Genomics, 2021, 24, 291-303.	0.6	5
201	Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression. Journal of Genetic Counseling, 2022, 31, 218-229.	0.9	5
202	Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences.. Journal of Clinical Oncology, 2017, 35, 6597-6597.	0.8	5
203	Child and Parent Understanding of Clinical Trials: The Semi-Structured Comprehension Interview. AJOB Empirical Bioethics, 2015, 6, 23-32.	0.8	4
204	Physicians and Insider Trading. JAMA Internal Medicine, 2015, 175, 1955.	2.6	4
205	â€œBig dataâ€•gets personal. Science Translational Medicine, 2016, 8, 322fs3-3fs3.	5.8	4
206	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. JAMA Oncology, 2018, 4, 1041.	3.4	4
207	Primary care providersâ€™ responses to unsolicited Lynch syndrome secondary findings of varying clinical significance. Genetics in Medicine, 2021, 23, 1977-1983.	1.1	4
208	Procedure-specific consent is the norm in United States intensive care units. Intensive Care Medicine, 2016, 42, 1637-1638.	3.9	3
209	Will my child do better if she enrolls in a clinical trial?. Cancer, 2018, 124, 3965-3968.	2.0	3
210	Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients. Npj Genomic Medicine, 2021, 6, 72.	1.7	3
211	Knowledge of Pediatric Ethics: Results of a Survey of Pediatric Ethics Consultants. AJOB Empirical Bioethics, 2015, 6, 19-30.	0.8	2
212	The Multidimensional Illness Severity Questionnaire: Preliminary evaluation of a brief parentâ€reported measure of illness severity. Journal of Paediatrics and Child Health, 2019, 55, 1241-1246.	0.4	2
213	Airmen and health-care providersâ€™ attitudes toward the use of genomic sequencing in the US Air Force: findings from the MilSeq Project. Genetics in Medicine, 2020, 22, 2003-2010.	1.1	2
214	The formation of the advisory group on risk evaluation education for dementia. Alzheimer's and Dementia, 2020, 16, e045562.	0.4	2
215	Reevaluating the â€œright not to knowâ€•in genomics research. Genetics in Medicine, 2022, 24, 289-292.	1.1	2
216	O3-02-01: DIRECT-TO-CONSUMER GENETIC TESTING FOR RISK OF ALZHEIMER'S DISEASE (AD): THE PSYCHOLOGICAL AND BEHAVIORAL IMPACT OF APOE GENOTYPE DISCLOSURE. , 2014, 10, P209-P209.		1

#	Article	IF	Citations
217	IC-P-042: Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P36-P36.		1
218	P1-201: Genetic findings using ADNI multimodal quantitative phenotypes: A 2014 update. , 2015, 11, P426-P426.		1
219	P1-139: Using the capacity assessment tool for genetic testing (CAT-GT) to assess the ability of persons with MCI to decide about ApoE testing: The reveal study. , 2015, 11, P395-P396.		1
220	O3-13-04: Genome-wide rare variant analysis identifies candidate genes significantly associated with composite scores for memory. , 2015, 11, P251-P252.		1
221	Ethical Testing of Experimental Ebola Treatmentsâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 313, 422.	3.8	1
222	The Role of Patient Perspectives in Clinical Research Ethics and Policy: Response to Open Peer Commentaries on â€œPatient Perspectives on the Learning Health Systemâ€• American Journal of Bioethics, 2016, 16, W7-W9.	0.5	1
223	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	0.8	1
224	The future of genomics in Ireland â€“ focus on genomics for health. HRB Open Research, 2020, 3, 89.	0.3	1
225	O2-02-01: Caregiver Agreeableness, Neuroticism, Openness and Extraversion Associated with Cognitive Decline in Persons with Alzheimer's Disease: The Cache County Dementia Progression Study. , 2011, 7, S290-S290.		0
226	O3-02-06: WHAT IS THE LONG-TERM EMOTIONAL AND BEHAVIORAL IMPACT OF GENETIC RISK ASSESSMENT FOR ALZHEIMER'S DISEASE? FINDINGS FROM THE REVEAL STUDY. , 2014, 10, P211-P211.		0
227	P3-014: Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P624-P625.		0
228	O4-05-01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target. , 2015, 11, P277-P278.		0
229	P2-016: Identification of genetic variants associated with Alzheimer's disease: Progression rate. , 2015, 11, P487-P487.		0
230	F3-03-01: Disclosing ApoE genotype status to individuals at risk for Alzheimer's disease: Applying lessons learned from the reveal study to prevention treatment trials. , 2015, 11, P214-P214.		0
231	Patient-Physician Relationship in the Age of Expanded Access to Informationâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1633.	3.8	0
232	Challenges in Research on Suicide Preventionâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1105.	3.8	0
233	Historical trends in health care-related financial holdings among members of Congress. PLoS ONE, 2021, 16, e0253624.	1.1	0
234	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Blood, 2014, 124, 209-209.	0.6	0

#	Article	IF	Citations
235	Informed consent from the doctor?. Hastings Center Report, 2004, 34, 12; discussion 12-3.	0.7	0
236	How knowledge of elevated amyloid impacts neuropsychological performance in cognitively normal older adults: Findings from the REVEAL SCAN Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0